Overview

New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.

Ultra-rapid acting insulin lispro (Lyumjev®▼, Lilly) is a new formulation of insulin lispro with added treprostinil and citrate to produce a more rapid onset of action. It is the second ultra-rapid acting insulin analogue to be launched after Fiasp®▼.

Download the full review below to read more.

NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 30th of June 2024.
For more information visit www.nice.org/accreditation